Welcome to our dedicated page for Arcus Bioscience SEC filings (Ticker: RCUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arcus Biosciences, Inc. (NYSE: RCUS) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company focused on oncology and inflammatory and autoimmune diseases, Arcus uses SEC filings to report material clinical, financial and corporate events that can be important for investors analyzing RCUS stock.
Form 8‑K current reports frequently highlight significant developments in Arcus’s pipeline and capital structure. For example, 8‑K filings describe the discontinuation of the Phase 3 STAR‑221 trial and the Phase 2 EDGE‑Gastric study after an interim overall survival analysis showed no benefit for the domvanalimab plus zimberelimab and chemotherapy regimen compared with nivolumab plus chemotherapy. Other 8‑Ks detail updated data from the ARC‑20 Phase 1/1b study of casdatifan in metastatic clear cell renal cell carcinoma, including progression-free survival and response metrics, as well as safety findings.
Filings also cover financing and capital markets transactions. One Form 8‑K outlines an underwriting agreement for a public offering of common stock, including the number of shares sold, pricing and net proceeds. Another 8‑K describes a First Amendment to the company’s Loan and Security Agreement with Hercules Capital and other lenders, which restructures remaining term loan commitments into milestone-based tranches tied to Phase 3 data and potential FDA approval, extends the maturity date and adds performance covenants linked to market capitalization, qualified cash levels and potential net product revenue thresholds.
Investors can also use SEC filings to track collaboration and licensing arrangements, such as disclosures related to Arcus’s long-term collaboration with Gilead Sciences and its option and license agreement with Taiho Pharmaceutical. These documents may reference option exercises, milestone structures and rights to co-develop or commercialize investigational medicines like casdatifan, domvanalimab, zimberelimab and quemliclustat in specific territories.
Stock Titan’s interface surfaces these filings alongside AI-powered summaries that explain the practical implications of each document. Instead of parsing detailed legal language alone, readers can review concise explanations of how a loan amendment changes Arcus’s access to capital, what a trial discontinuation means for a particular program, or how a new data disclosure from a Phase 1/1b or Phase 3 study might influence the company’s development strategy. Real-time updates from EDGAR, combined with these AI insights, help users follow Arcus’s quarterly results, material clinical events, financing decisions and collaboration milestones directly from the underlying SEC record.
Arcus Biosciences Chief Medical Officer Markus Richard received new equity awards. On January 23, 2026, he was granted 24,000 shares of common stock in the form of restricted stock units at a grant price of $0. These RSUs vest in four equal annual installments beginning on December 15, 2026, as long as he continues to serve the company.
He was also granted a stock option for 96,000 shares of common stock with an exercise price of $22.13 per share. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, contingent on his continued service. After these grants, he beneficially owned 89,647 shares of common stock directly and 96,000 stock options.
Arcus Biosciences Chief Executive Officer Terry J. Rosen reported new equity awards. On January 23, 2026, he received 79,000 shares of common stock in the form of restricted stock units at a grant price of
On the same date, he was also granted stock options for 315,000 shares of Arcus common stock with an exercise price of
Arcus Biosciences, Inc. reported new equity awards for President Juan C. Jaen. On January 23, 2026, he received 31,000 shares of common stock as restricted stock units at a grant price of $0. These RSUs vest in four equal annual installments beginning December 15, 2026, contingent on his continued service, bringing his directly held common stock to 377,012 shares, including unvested RSUs. He also received a stock option for 126,000 shares of common stock with an exercise price of $22.13 per share. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, and all 126,000 option shares are reported as directly owned. In addition, 922,240 shares of common stock are reported as indirectly owned through a trust.
Arcus Biosciences granted equity awards to its General Counsel, Carolyn C. Tang. She received 24,000 shares of common stock in the form of restricted stock units at a grant price of
She was also granted a stock option for 96,000 shares of common stock with an exercise price of
Arcus Biosciences granted Chief Financial Officer Robert C. Goeltz II new equity awards. On 01/23/2026, he received 24,000 shares of common stock in the form of restricted stock units at a grant price of $0. These RSUs vest in four equal annual installments beginning on December 15, 2026, as long as he continues serving the company.
He was also granted a stock option to buy 96,000 shares of common stock at an exercise price of $22.13 per share. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to his continued service. Following the RSU grant, he beneficially owned 91,924 shares of common stock directly, which includes unvested RSUs.
Arcus Biosciences Chief Accounting Officer Alexander Azoy received new equity awards in the form of restricted stock units and stock options. On January 23, 2026, he was granted 21,050 shares of Common Stock as restricted stock units at a price of $0. These RSUs vest in four equal annual installments beginning on December 15, 2026, as long as he continues serving the company.
On the same date, he also received a stock option to buy 14,050 shares of Common Stock at an exercise price of $22.13 per share, with no cost for the grant itself. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to his continued service. After these transactions, he beneficially owned 39,581 shares of Common Stock, including unvested RSUs, held directly.
Arcus Biosciences Chief Operating Officer receives new equity awards. On January 23, 2026, COO Jennifer Jarrett was granted 31,000 shares of common stock in the form of restricted stock units, which vest in four equal annual installments beginning on December 15, 2026, as long as she continues serving the company. She also received a stock option covering 126,000 shares of common stock at an exercise price of $22.13 per share. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to her continued service. Following these grants, she directly holds 224,024 shares of common stock, including unvested RSUs, and 126,000 stock options.
Arcus Biosciences Chief Executive Officer and director Terry J. Rosen reported a charitable gift of company stock. On 01/08/2026, Rosen donated 35,000 shares of Arcus Biosciences, Inc. common stock, coded as a charitable gift transaction. The shares were transferred at a reported price of $0 per share, consistent with a non-cash donation. After this gift, Rosen beneficially owned 2,157,409 shares of common stock, which the disclosure notes includes the unvested portion of his restricted stock unit grants. This filing updates the market on Rosen’s current direct equity stake in the company.
BlackRock, Inc. reports beneficial ownership of 12,736,927 shares of Arcus Biosciences common stock, representing 10.4% of the outstanding class as of the event date. BlackRock has sole voting power over 12,575,912 shares and sole dispositive power over 12,736,927 shares, with no shared voting or dispositive power.
The filing states that various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Arcus Biosciences’ common shares. BlackRock certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Arcus Biosciences president Juan C. Jaen reported indirect sales of Arcus Biosciences common stock held by a trust associated with him. On January 5, 2026, the trust sold 29,670 shares at a weighted average price of $21.34, 2,053 shares at a weighted average price of $22.34, and 100 shares at $23.20, under a Rule 10b5-1 trading plan adopted on August 8, 2025.
Following these transactions, the trust continued to hold 922,240 shares of Arcus Biosciences common stock. Jaen also reported 346,012 shares held directly, which include the unvested portion of his restricted stock unit grants.
FAQ
What is the current stock price of Arcus Bioscience (RCUS)?
What is the market cap of Arcus Bioscience (RCUS)?
